Elutia (ELUT) to Post Earnings on Thursday

Elutia (NASDAQ:ELUT) is anticipated to announce its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to post earnings of ($0.15) per share and revenue of $2.90 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 5:00 PM ET.

Elutia (NASDAQ:ELUT) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The business had revenue of $3.11 million during the quarter, compared to the consensus estimate of $3.00 million.

Elutia Price Performance

Shares of Elutia stock opened at $0.87 on Thursday. Elutia has a fifty-two week low of $0.50 and a fifty-two week high of $2.50. The business’s fifty day moving average is $0.97 and its two-hundred day moving average is $1.03. The firm has a market cap of $37.30 million, a PE ratio of 1.01 and a beta of 0.87.

Hedge Funds Weigh In On Elutia

Several institutional investors and hedge funds have recently bought and sold shares of ELUT. Virtu Financial LLC acquired a new position in shares of Elutia in the 3rd quarter valued at $26,000. XTX Topco Ltd purchased a new stake in shares of Elutia during the 2nd quarter valued at $28,000. Jane Street Group LLC acquired a new stake in shares of Elutia during the 1st quarter worth $48,000. Citadel Advisors LLC acquired a new stake in shares of Elutia during the 3rd quarter worth $50,000. Finally, Renaissance Technologies LLC raised its position in shares of Elutia by 64.7% in the 4th quarter. Renaissance Technologies LLC now owns 102,116 shares of the company’s stock worth $71,000 after buying an additional 40,123 shares during the period. Institutional investors and hedge funds own 74.03% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Elutia from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 23rd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $6.00.

Elutia Company Profile

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.